Amicus Therapeutics Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Amicus Therapeutics Value Chain Analysis gives you a clear, structured view of how the company creates value across support and primary activities, and what it is used for in research, strategy, and investing. This page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Amicus Therapeutics uses a centralized firm infrastructure built for a rare-disease biotech with 2 marketed therapies, so finance, legal, quality, compliance, and portfolio oversight stay tightly aligned.
That setup helps Amicus Therapeutics make faster global decisions across regulators, payers, and commercial teams while keeping spending focused on a small program base.
In 2025, this lean structure is a key support activity because it reduces duplication and helps Amicus Therapeutics prioritize execution on Galafold and Pombiliti + Opfolda.
Human Resource Management
Amicus Therapeutics depends on specialized scientists, regulatory experts, medical affairs staff, and rare-disease commercial leaders to keep genetics, reimbursement, manufacturing, and launch work aligned. In FY2025, that mix of skills mattered because rare-disease drug launches need fast decisions and tight cross-functional execution, not siloed teams. Hiring and retaining this talent supports compliance, faster market access, and smoother product rollout.
Technology Development
Amicus Therapeutics uses translational science in Fabry and Pompe to turn disease biology into products; its technology base supports 2 approved therapies, Galafold and Pombiliti/Opfolda. In 2025, R&D stayed a core spend, funding clinical development, formulation work, and process upgrades that improve delivery and product durability. This tech layer helps Amicus extend lifecycle value and support long-term margin quality.
Procurement
Procurement at Amicus Therapeutics centers on qualified suppliers for active ingredients, biologics inputs, packaging, cold-chain services, and contract manufacturing capacity. This sourcing mix lowers supply risk and helps keep commercial and clinical material available for rare-disease patients.
Because rare-disease demand can be small but urgent, supplier quality and backup capacity matter as much as price. Tight procurement control also supports continuity for therapies such as Galafold and Pombiliti+Opfolda.
Amicus Keeps FY2025 Support Lean Behind 2 Therapies
Amicus Therapeutics keeps support activities lean in FY2025, with centralized finance, legal, quality, compliance, and portfolio control built around 2 marketed therapies.
Its talent base of scientists, regulatory staff, and rare-disease commercial leaders supports faster decisions across reimbursement, manufacturing, and launch work.
R&D and tech spending still back Galafold and Pombiliti + Opfolda, while procurement focuses on qualified suppliers, packaging, and contract manufacturing.
| FY2025 support driver | Key data |
|---|---|
| Marketed therapies | 2 |
| Core support functions | Finance, legal, quality, compliance |
| Priority products | Galafold; Pombiliti + Opfolda |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Inbound logistics at Amicus Therapeutics centers on receipt, qualification, and cold-chain storage of raw materials, drug substance, packaging, and other temperature-sensitive inputs. For rare-disease patients, any stockout can disrupt daily therapy, so supplier qualification and inventory control must stay tight. Amicus Therapeutics backed this with a 2024 net product sales base of $483.3 million, showing how supply continuity supports revenue delivery.
Operations
Amicus Therapeutics' operations are built around 2 approved rare-disease medicines, Galafold and Pombiliti/Opfolda, so the work is clinical, not factory-heavy. In FY2025, the value chain still centered on trial execution, tech transfer, quality checks, and batch release to keep supply steady.
This means Amicus Therapeutics turns science into medicine through manufacturing oversight and regulatory maintenance, rather than large internal production runs. For investors, that lowers capex intensity but makes execution, partner quality, and compliance critical to revenue continuity.
Outbound Logistics
Amicus Therapeutics uses specialty distributors, wholesalers, and hospital infusion channels to move therapies across markets, so outbound logistics has to fit both Galafold's oral chronic supply and Pombiliti plus Opfolda's infused flow. In 2025, its products were sold in major regions including the U.S., Europe, and Japan, which raises the need for tight traceability and inventory timing. Cold-chain handling and clinic-level scheduling matter because infusion doses must arrive on time and intact.
Marketing and Sales
Amicus Therapeutics keeps marketing and sales tightly focused on metabolic specialists, geneticists, infusion centers, and payers, which fits a rare-disease model with a small patient pool. Its 2025 commercial effort depends on patient finding and faster diagnosis, since new prescriptions often start only after genetic testing and specialist referral. Reimbursement support also matters because durable demand comes from keeping therapy accessible after the first script.
Service
Amicus Therapeutics uses service to add medical information, patient support, adherence help, and adverse-event monitoring after launch. In rare disease, this post-sale layer helps keep patients on therapy and builds trust when treatment starts with genetic testing and long-term dosing.
It also matters for infused care, where scheduling and follow-up can affect persistence. For Amicus Therapeutics, service is not just support; it protects real-world use and helps sustain value after approval.
Amicus Therapeutics' FY2025: Tight Ops, Specialist Sales, Rare-Disease Reach
Amicus Therapeutics' primary activities in FY2025 were lean and commercial: 2 approved rare-disease medicines, Galafold and Pombiliti/Opfolda, had to move through tight manufacturing oversight, batch release, and quality control. Sales, too, stayed specialist-led, reaching patients through genetic testing, payer access, and infusion-center scheduling across the U.S., Europe, and Japan. Service then protected persistence with medical information, adherence help, and adverse-event follow-up.
| FY2025 item | Value |
|---|---|
| Approved medicines | 2 |
| Core markets | 3 |
| Primary commercial need | Patient finding |
Preview Before You Purchase
Amicus Therapeutics Reference Sources
This is the actual Amicus Therapeutics Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is exactly what you'll get. Purchase unlocks the complete in-depth version for immediate use.
Frequently Asked Questions
Amicus Therapeutics' value chain is driven most by operations and commercialization. It has 2 marketed therapies, Galafold and Pombiliti/Opfolda, across 2 core rare-disease franchises, so clinical execution and market access matter more than scale manufacturing. The business depends on specialist prescribers, reimbursement, and reliable supply for small patient populations.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.